# US 2021/0261545 A1 · Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261545 A1
- Document ID: US20210261545A1
- Status: Published application
- Kind: A1
- Application number: 17/254,071
- Filed: 2019-06-18
- Published: 2021-08-26
- Earliest claimed: 2018-06-21
- Assignees: Heparegenix GmbH
- Applicants: Heparegenix GmbH
- Inventors: Michael JUCHUM; Roland SELIG; Stefan LAUFER; Wolfgang ALBRECHT
- Web page: https://patentgrep.com/patent/US20210261545A1

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- C07D 471/04: Ortho-condensed systems
- A61P 31/20: for DNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to tricyclic compounds which are MKK4 (mitogen-activated protein kinase kinase 4) inhibitors which selectively inhibit protein kinase kinase MKK4 over protein kinases JNK and MKK7. They are useful for promoting liver regeneration or reducing or preventing hepatocyte death.

## Claims

### Claim 1

A compound having formula (I) and the pharmaceutically acceptable salts, solvates and optical isomers thereof,
wherein the variables in formula (I) have the meanings as follows:
R1 is H or alkyl;
R2 is H or alkyl;
R3 is H or alkyl;
Q is phenyl, which is substituted with Ra and is optionally substituted with Rb, Rc, Rd and Re;
Ra is —NR10SO2R12, —NR10SO2NR10R12 or —N═S(═O)R10NR10R10;
Rb, Rc, Rd and Re are independently selected from
a) H,
b) alkyl which is optionally substituted with 1 or 2 substituents independently selected from phenyl, halogen substituted phenyl, halogen, OH, CN, and —NR10R10, and
c) halogen,
wherein at least one of Rb, Rc, Rd and Re is halogen
R4 is H or alkyl;
R5 is selected from
a) halogen;
b) phenyl or naphthyl which phenyl or naphthyl is optionally substituted with 1, 2 or 3 groups independently selected from halogen, hydroxy, R11O—, —COOR10, R10OCO—, R10R10N—CO—, R10R11NSO2—, and a heteroaromatic 5- or 6-membered monocyclic or heteroaromatic 9- or 10-membered bicyclic group having 1, 2, 3 or 4 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from alkyl, alkoxy, halogen, —NR10R10, and alkyl which is optionally substituted with 1, 2 or 3 hydroxy groups, and
c) a heteroaromatic 5- or 6-membered monocyclic or heteroaromatic 9- or 10-membered bicyclic group having 1 to 3 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from —NR10R10, R10R11N—SO2—, R10R11N—CO— and a heteroaromatic 5- or 6-membered group having 1 or 2 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from alkyl, alkoxy, halogen, —NR10R10, and alkyl which is optionally substituted with 1, 2 or 3 hydroxy groups;
R6 is H or alkyl;
R10 at each occurrence independently is H, alkyl, phenyl, which is optionally substituted with 1 or 2 hydroxyl or alkoxy groups, or is phenylalkyl wherein the phenyl group is optionally substituted with halogen or alkyl;
R11 is H, or alkyl, which is optionally substituted with 1 or 2 hydroxy groups;
R12 is
alkyl, which is optionally substituted with 1 or 2 groups independently selected from halogen, phenyl and cycloalkyl,

### Claim 2 (depends on 1)

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of claim 1, wherein R5 is selected from
a) halogen,
b) phenyl which is optionally substituted with 1, 2 or 3 groups independently selected from halogen, hydroxy, R11O—, —COOR10, R10R10N—CO—, R10R11NSO2—, and a heteroaromatic 5- or 6-membered monocyclic group having 1, 2, 3 or 4 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from alkyl, alkoxy, halogen,
—NR10R10, and alkyl which alkyl is optionally substituted with 1, 2 or 3 hydroxy groups, and
c) a heteroaromatic 5- or 6-membered monocyclic group having 1 to 3 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from —NR10Rc, R10R11N—SO2—, R10R11N—CO— and a heteroaromatic 5- or 6-membered group having 1 or 2 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from alkyl, alkoxy, halogen,
—NR10R10, and alkyl which is optionally substituted with 1, 2 or 3 hydroxy groups.

### Claim 3

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, having formula

### Claim 4

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims having formula (Ib) or (Ic)

### Claim 5

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein
R5 is selected from
a) halogen,
b) phenyl which is optionally substituted with 1 or 2 groups independently selected from halogen, hydroxy, R11O—, COOR10, R10R10N—CO—, R10R11NSO2—, and tetrazolyl, and
c) pyridyl which is optionally substituted with 1 or 2 groups independently selected from —NR10R10, R10R11N—SO2—, R10R11N—CO— and pyrrolyl which is optionally substituted with 1 or 2 alkyl groups.

### Claim 6

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein Ra is —NR10SO2R12, and R12 is alkyl.

### Claim 7

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein
a) Rb and Re are both halogen, in particular fluorine, or
b) Rb and Rc are both halogen, in particular fluorine.

### Claim 8

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein R1, R2, R3, R4, and R6 are H.

### Claim 9

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein R10 is H or alkyl.

### Claim 10

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein R11 is alkyl, in particular C2-, C3- or C4-alkyl.

### Claim 11

The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, selected from the group consisting of

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising a compound of any one of claims 1 to 11 and the pharmaceutically acceptable salts, solvates and optical isomers thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof according to any one of claims 1 to 11 for use in selectively inhibiting protein kinase MKK4 over protein kinases JNK1 and MKK7.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof according to any one of claims 1 to 11 for use in promoting liver regeneration or preventing hepatocyte death.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof according to any one of claims 1 to 11 for use in the treatment of acute, acute-on-chronic or chronic liver disease or for treating osteoarthritis or rheumatoid arthritis.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof according to any one of claims 1 to 11 for use in treating
acute and chronic or acute on chronic liver diseases such as acute and chronic viral hepatitis like hepatitis B, C, E, hepatitis caused by Epstein-Barr virus, cytomegalovirus, herpes simplex virus and other viruses, all types of autoimmune hepatitis, primary sclerosing hepatitis, alcoholic hepatitis;
metabolic liver diseases such as metabolic syndrome, fatty liver like non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), Morbus Wilson, hemochromatosis, alpha1-antitrypsin deficiency, glycogen storage diseases;
all types of liver cirrhosis, such as primary biliary cirrhosis, ethyl toxic liver cirrhosis, cryptogenic cirrhosis;
acute (fulminant) or chronic liver failure such as toxic liver failure like acetaminophen (paracetamol) induced liver failure, alpha-amanitin induced liver failure, drug induced hepatotoxicity and liver failure caused, for example, by antibiotics, nonsteroidal anti-inflammatory drugs, anticonvulsants, acute liver failure induced by herbal supplements (kava, ephedra, skullcap, pennyroyal etc.), liver disease and failure due to vascular diseases such as Budd-Chiari syndrome, acute liver failure of unknown origin, chronic liver disease due to right heart failure;
galactosemia, cystic fibrosis, porphyria, hepatic ischemia perfusion injury, small for size syndrome after liver transplantation, primary sclerosing cholangitis or hepatic encephalopathy.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of selectively inhibiting protein kinase MKK4 over protein kinases JNK1 and MKK7, promoting liver regeneration or preventing hepatocyte death, the treatment of acute,
acute-on-chronic or chronic liver disease, for treating acute and chronic or acute on chronic liver diseases such as acute and chronic viral hepatitis like hepatitis B, C, E, hepatitis caused by Epstein-Barr virus, cytomegalovirus, herpes simplex virus and other viruses, all types of autoimmune hepatitis, primary sclerosing hepatitis, alcoholic hepatitis;
metabolic liver diseases such as metabolic syndrome, fatty liver like non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), Morbus Wilson, hemochromatosis, alpha1-antitrypsin deficiency, glycogen storage diseases;
all types of liver cirrhosis, such as primary biliary cirrhosis, ethyl toxic liver cirrhosis, cryptogenic cirrhosis;
acute (fulminant) or chronic liver failure such as toxic liver failure like acetaminophen (paracetamol) induced liver failure, alpha-amanitin induced liver failure, drug induced hepatotoxicity and liver failure caused, for example, by antibiotics, nonsteroidal anti-inflammatory drugs, anticonvulsants, acute liver failure induced by herbal supplements (kava, ephedra, skullcap, pennyroyal etc.), liver disease and failure due to vascular diseases such as Budd-Chiari syndrome, acute liver failure of unknown origin, chronic liver disease due to right heart failure;
galactosemia, cystic fibrosis, porphyria, hepatic ischemia perfusion injury, small for size syndrome after liver transplantation, primary sclerosing cholangitis or hepatic encephalopathy,
or for treating osteoarthritis or rheumatoid arthritis,
which comprises administering an effective amount of a compound or a composition as defined in any one of claim 1 to 12 to a subject in need thereof.
